Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
9 papers
Recent·Most cited
A. S. Espinoza, R. N. McVicar, D. Finlay, R. Murad, K. Vuori, B. A. Grimmig, A. Bush, E. Smith, T. Mandel-Clausen, H. M. McGee, E. Y. Snyder, S. L. Leibel
This study compares 3D tumoroid and 2D cultures of lung cancer cells to assess how cell-cell orientation affects cancer-related features and finds that 3D cultures better mimic primary human lung cancer.
bioRxiv · Dec 30, 2023 · PreprintCancer Biology
A. Kuhlmann-Hogan, T. Cordes, Z. Xu, K. Traina, C. Robles-Oteiza, D. Ayeni, E. M. Kwong, S. Levy, M. Nobari, G. Z. Cheng, R. J. Shaw, S. L. Leibel, C. Metallo, K. Politi, S. M. Kaech
This study shows EGFR-mutant lung adenocarcinomas exploit alveolar macrophage metabolism via GM-CSF--PPARγ signaling to support tumor growth and EGFR signaling, suggesting new therapeutic strategies combining statins and PPARγ inhibition.
bioRxiv · Apr 15, 2023 · PreprintImmunology
S. L. Leibel, R. N. McVicar, R. Murad, E. M. Kwong, A. E. Clark, A. Alvarado, B. A. Grimmig, R. Nuryyev, R. E. Young, J. C. Lee, W. Peng, Y. P. Zhu, E. Griffis, C. J. Nowell, B. James, , E. Y. Snyder
This study shows that surfactant proteins mediate an intrinsic inflammatory response in the lung to defend against SARS-CoV-2 infection.
bioRxiv · Jan 26, 2023 · PreprintImmunology
R. Li, M. Mor, B. Ma, A. E. Clark, J. Alter, M. Werbner, J. Lee, S. L. Leibel, A. F. Carlin, M. Dassau, M. Gal-Tanamy, B. A. Croker, Y. Xiang, N. T. Freund
This study evaluates the neutralizing activity of nine anti-SARS-CoV-2 monoclonal antibodies against variants of concern and reveals their structural mechanisms of action.
bioRxiv · Apr 3, 2022Immunology
R. T. Schooley, A. F. Carlin, J. R. Beadle, N. Valiaeva, X.-Q. Zhang, A. E. Clark, R. E. McMillian, S. L. Leibel, R. N. McVicar, J. Xie, A. F. Garretson, V. I. Smith, J. A. Murphy, K. Y. Hostetler
This paper develops orally bioavailable lipid prodrugs of Remdesivir that show submicromolar anti-SARS-CoV-2 activity and therapeutic plasma levels in Syrian hamsters.
Antimicrobial Agents and Chemotherapy · Sep 17, 2021Peer-reviewedMicrobiology
R. A. Salido, V. J. Cantu, A. E. Clark, S. L. Leibel, A. Foroughishafiei, A. Saha, A. Hakim, A. Nouri, A. L. Lastrella, A. Castro-Martinez, A. Plascencia, B. Kapadia, B. Xia, C. Ruiz, C. Marotz, , R. Knight
This study compares RT-qPCR signal intensity and persistence of heat-inactivated and infectious SARS-CoV-2 on different surfaces, showing similar decay patterns and enabling simplified environmental monitoring protocols.
bioRxiv · Jul 16, 2021 · PreprintMicrobiology
D. R. Sandoval, T. Mandel Clausen, C. Nora, J. A. Magida, A. P. Cribbs, A. Denardo, A. E. Clark, A. F. Garretson, J. K. C. Coker, A. Narayanan, S. A. Majowicz, M. Philpott, C. Johansson, J. E. Dunford, C. B. Spliid, , Mazitsch
This study identifies halofuginone as a potent inhibitor of SARS-CoV-2 infection and replication by reducing heparan sulfate biosynthesis and suppressing viral replication.
bioRxiv · Mar 22, 2021 · PreprintMicrobiology
T. M. Clausen, D. R. Sandoval, C. B. Spliid, J. Pihl, C. D. Painter, B. E. Thacker, C. A. Glass, A. Narayanan, S. A. Majowicz, Y. Zhang, J. L. Torres, G. J. Golden, R. Porell, A. F. Garretson, L. Laubach, , J. D. Esko
This study shows SARS-CoV-2 spike protein binds to heparan sulfate and ACE2 on cells codependently, forming a complex that facilitates infection, suggesting potential therapeutic targets.
Cell · Nov 1, 2020Peer-reviewedMicrobiology
M. Mor, M. Werbner, J. Alter, M. Safra, E. Chomsky, S. Hada-Neeman, K. Polonsky, C. Nowell, A. Clark, A. Roitburd-Berman, N. Ben-Shalom, M. Navon, D. Rafael, H. Sharim, E. Kiner, , N. Freund
This study identifies multi-clonal neutralizing antibodies against SARS-CoV-2 in severe COVID-19 patients and shows their potential for combination therapy.
bioRxiv · Oct 6, 2020Immunology